BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 24698979)

  • 1. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease.
    Hsiao HY; Chiu FL; Chen CM; Wu YR; Chen HM; Chen YC; Kuo HC; Chern Y
    Hum Mol Genet; 2014 Aug; 23(16):4328-44. PubMed ID: 24698979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington's disease.
    Hsiao HY; Chen YC; Chen HM; Tu PH; Chern Y
    Hum Mol Genet; 2013 May; 22(9):1826-42. PubMed ID: 23372043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
    Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
    Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
    Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
    J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5/RANTES) by astrocytes.
    Chou SY; Weng JY; Lai HL; Liao F; Sun SH; Tu PH; Dickson DW; Chern Y
    J Neurosci; 2008 Mar; 28(13):3277-90. PubMed ID: 18367595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Expression of Foxp1 as a Contributing Factor in Huntington's Disease.
    Louis Sam Titus ASC; Yusuff T; Cassar M; Thomas E; Kretzschmar D; D'Mello SR
    J Neurosci; 2017 Jul; 37(27):6575-6587. PubMed ID: 28550168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Astrocytes from cortex and striatum show differential responses to mitochondrial toxin and BDNF: implications for protection of striatal neurons expressing mutant huntingtin.
    Saba J; López Couselo F; Turati J; Carniglia L; Durand D; de Laurentiis A; Lasaga M; Caruso C
    J Neuroinflammation; 2020 Oct; 17(1):290. PubMed ID: 33023623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.
    Lim NK; Hung LW; Pang TY; Mclean CA; Liddell JR; Hilton JB; Li QX; White AR; Hannan AJ; Crouch PJ
    Hum Mol Genet; 2014 Aug; 23(15):4051-63. PubMed ID: 24634145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
    Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
    Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease.
    Chiang MC; Chern Y; Huang RN
    Neurobiol Dis; 2012 Jan; 45(1):322-8. PubMed ID: 21907283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating the role of the A2A adenosine receptor in neurodegeneration using neurons derived from Huntington's disease iPSCs.
    Chiu FL; Lin JT; Chuang CY; Chien T; Chen CM; Chen KH; Hsiao HY; Lin YS; Chern Y; Kuo HC
    Hum Mol Genet; 2015 Nov; 24(21):6066-79. PubMed ID: 26264576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.
    Miguez A; García-Díaz Barriga G; Brito V; Straccia M; Giralt A; Ginés S; Canals JM; Alberch J
    Hum Mol Genet; 2015 Sep; 24(17):4958-70. PubMed ID: 26063761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with JQ1, a BET bromodomain inhibitor, is selectively detrimental to R6/2 Huntington's disease mice.
    Kedaigle AJ; Reidling JC; Lim RG; Adam M; Wu J; Wassie B; Stocksdale JT; Casale MS; Fraenkel E; Thompson LM
    Hum Mol Genet; 2020 Jan; 29(2):202-215. PubMed ID: 31696228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant astrocytes impair vascular reactivity in Huntington disease.
    Hsiao HY; Chen YC; Huang CH; Chen CC; Hsu YH; Chen HM; Chiu FL; Kuo HC; Chang C; Chern Y
    Ann Neurol; 2015 Aug; 78(2):178-92. PubMed ID: 25914140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.
    Denovan-Wright EM; Attis M; Rodriguez-Lebron E; Mandel RJ
    J Neurosci Res; 2008 Jun; 86(8):1748-57. PubMed ID: 18293418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease.
    Alto LT; Chen X; Ruhn KA; Treviño I; Tansey MG
    PLoS One; 2014; 9(5):e96544. PubMed ID: 24824433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin.
    Naia L; Ribeiro M; Rodrigues J; Duarte AI; Lopes C; Rosenstock TR; Hayden MR; Rego AC
    Neuropeptides; 2016 Aug; 58():73-81. PubMed ID: 26876526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
    Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
    Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington's disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number.
    Rossignol J; Fink KD; Crane AT; Davis KK; Bombard MC; Clerc S; Bavar AM; Lowrance SA; Song C; Witte S; Lescaudron L; Dunbar GL
    Stem Cell Res Ther; 2015 Feb; 6(1):9. PubMed ID: 25971780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.